| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jeffrey M Cochran, Hui Fang, Christophe Le Gallo, Timothy Peters-Strickland, Jean-Pierre Lindenmayer, J Corey Reuteman-Fowle. Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia. Patient preference and adherence. vol 16. 2022-08-04. PMID:35923658. |
a recent, phase 3b, mirror-image clinical trial of outpatients with schizophrenia found that use of aripiprazole tablets with sensor (as; abilify mycite |
2022-08-04 |
2023-08-14 |
human |
| Dalia A Nawwar, Hala F Zaki, Rabab H Saye. Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. Inflammopharmacology. 2022-07-25. PMID:35876932. |
this study investigates the effects of aripiprazole and sertindole on the nrg1/erbb4 and pi3k/akt/mtor signaling pathways in ketamine-induced schizophrenia in rats. |
2022-07-25 |
2023-08-14 |
rat |
| David Fraguas, David Almenta Gallego, Sergio Arques-Egea, Marcos Gómez-Revuelta, Carlos Gómez Sánchez-Lafuente, Daniel Hernández Huerta, Daniel Núñez Arias, Beatriz Oda Plasencia-García, Carlos Parro Torres, Samuel Leopoldo Romero-Guillena, Elena Ros Cucurul, Cecilio Alam. Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice. International journal of psychiatry in clinical practice. 2022-07-06. PMID:35792729. |
aripiprazole for the treatment of schizophrenia: recommendations of a panel of spanish experts on its use in clinical practice. |
2022-07-06 |
2023-08-14 |
Not clear |
| Taro Kishi, Kenji Sakuma, Nakao Iwat. Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis. Pharmacopsychiatry. 2022-07-05. PMID:35790191. |
aripiprazole once-monthly versus oral aripiprazole for schizophrenia in the maintenance phase: a systematic review and network meta-analysis. |
2022-07-05 |
2023-08-14 |
Not clear |
| Taro Kishi, Kenji Sakuma, Nakao Iwat. Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis. Pharmacopsychiatry. 2022-07-05. PMID:35790191. |
to examine whether aripiprazole once-monthly (aom) was more beneficial than oral aripiprazole (oari) in the treatment of adults with schizophrenia during the maintenance phase. |
2022-07-05 |
2023-08-14 |
Not clear |
| Guillaume Meyer, Clara Gitahy Falcao Faria, Marine Beck, Marielle Riutort, Bruno Michel, Hervé Javelo. Suicidality and psychotic episodes after starting aripiprazole: two case reports. International clinical psychopharmacology. 2022-06-13. PMID:35695655. |
here, we present two major psychotic decompensations that occurred following a switch to aripiprazole in two patients with schizophrenia. |
2022-06-13 |
2023-08-14 |
Not clear |
| Jaedeok Kim, Nayoung Lee, Sang Bum Suh, Sooyeon Jang, Saeha Kim, Dong-Gyu Kim, Jong Kook Park, Keun-Wook Lee, Soo Young Choi, Chan Hee Le. Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance. BMB reports. 2022-06-02. PMID:35651327. |
while atypical antipsychotics such as aripiprazole are not associated with obesity and diabetes, olanzapine is still widely used based on the anticipation that it is more effective in treating severe schizophrenia than aripiprazole, despite its metabolic side effects. |
2022-06-02 |
2023-08-13 |
mouse |
| Pierre-Michel Llorca, Philippe Nuss, Éric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, Stéphane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-Noëlle Vacheron, Jean-Michel Azori. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC psychiatry. vol 22. issue 1. 2022-06-01. PMID:35643542. |
place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a delphi consensus study. |
2022-06-01 |
2023-08-13 |
Not clear |
| Pierre-Michel Llorca, Philippe Nuss, Éric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, Stéphane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-Noëlle Vacheron, Jean-Michel Azori. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC psychiatry. vol 22. issue 1. 2022-06-01. PMID:35643542. |
aripiprazole is a second-generation antipsychotic, efficacious in patients with schizophrenia during acute episodes. |
2022-06-01 |
2023-08-13 |
Not clear |
| Jarosław Sobiś, Łukasz Kunert, Monika Rykaczewska-Czerwińska, Elżbieta Świętochowska, Piotr Gorczyc. The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. Endokrynologia Polska. vol 73. issue 1. 2022-04-05. PMID:35381103. |
the effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. |
2022-04-05 |
2023-08-13 |
Not clear |
| Jarosław Sobiś, Łukasz Kunert, Monika Rykaczewska-Czerwińska, Elżbieta Świętochowska, Piotr Gorczyc. The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. Endokrynologia Polska. vol 73. issue 1. 2022-04-05. PMID:35381103. |
the aim of this study was to test the effect of aripiprazole on leptin, insulin, acute phase proteins, and selected cytokines levels in patients with chronic schizophrenia. |
2022-04-05 |
2023-08-13 |
Not clear |
| Mette Ødegaard Nielsen, Tina Dam Kristensen, Kirsten Borup Bojesen, Birte Y Glenthøj, Cecilie K Lemvigh, Bjørn H Ebdru. Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses. Frontiers in psychiatry. vol 13. 2022-04-04. PMID:35370857. |
aripiprazole is hypothesized to have an effect on negative and cognitive symptoms in schizophrenia. |
2022-04-04 |
2023-08-13 |
Not clear |
| Zofia Rogóż, Kinga Kamińska, Marta Anna Lech, Elżbieta Lorenc-Koc. N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia. International journal of molecular sciences. vol 23. issue 4. 2022-02-26. PMID:35216241. |
n-acetylcysteine and aripiprazole improve social behavior and cognition and modulate brain bdnf levels in a rat model of schizophrenia. |
2022-02-26 |
2023-08-13 |
rat |
| Blanca Fernández-Abascal, Maria Recio-Barbero, Margarita Sáenz-Herrero, Rafael Segarr. Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. Therapeutic advances in psychopharmacology. vol 11. 2022-02-21. PMID:35186259. |
long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. |
2022-02-21 |
2023-08-13 |
Not clear |
| Virginio Salvi, Cristina Appignanesi, Brodinela Marpepa, Laura Orsolini, Umberto Volp. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports. 2022-02-19. PMID:35182040. |
aripiprazole lai two-injection start in a 16 year-old adolescent with schizophrenia. |
2022-02-19 |
2023-08-13 |
Not clear |
| Virginio Salvi, Cristina Appignanesi, Brodinela Marpepa, Laura Orsolini, Umberto Volp. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports. 2022-02-19. PMID:35182040. |
aripiprazole long-acting injection (lai) is approved for the treatment of schizophrenia in adults. |
2022-02-19 |
2023-08-13 |
Not clear |
| Virginio Salvi, Cristina Appignanesi, Brodinela Marpepa, Laura Orsolini, Umberto Volp. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports. 2022-02-19. PMID:35182040. |
aripiprazole showed efficacy in the treatment of adolescents with acute schizophrenia in several controlled trials, leading to its approval for 13- to 17-year-old adolescents with schizophrenia by the ema. |
2022-02-19 |
2023-08-13 |
Not clear |
| N V Baymeeva, I I Miroshnichenko, A I Platova, D V Tikhonov, V G Kaled. [Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 1. 2022-02-17. PMID:35175709. |
[therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. |
2022-02-17 |
2023-08-13 |
Not clear |
| N V Baymeeva, I I Miroshnichenko, A I Platova, D V Tikhonov, V G Kaled. [Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 1. 2022-02-17. PMID:35175709. |
to personalize pharmacotherapy with aripiprazole in patients with schizophrenia via therapeutic drug monitoring (tdm). |
2022-02-17 |
2023-08-13 |
Not clear |
| Pavel Mohr, Jirí Masopust, Miloslav Kopeče. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? Frontiers in psychiatry. vol 12. 2022-02-11. PMID:35145438. |
in two acute schizophrenia rcts of cariprazine and brexpiprazole, aripiprazole was used as an indirect comparator to control for study sensitivity. |
2022-02-11 |
2023-08-13 |
Not clear |